跳至主要内容
临床试验/EUCTR2021-001988-24-PL
EUCTR2021-001988-24-PL进行中(未招募)1 期

Prospective, randomized, double-blind, placebo-controlled, parallel-group trial with an open-label period to investigate the efficacy and safety of NT201 in the unilateral and bilateral treatment of essential tremor of the upper limb

Merz Pharmaceuticals GmbH0 个研究点目标入组 75 人开始时间: 2021年7月1日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
75

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Score of = 2 (at least 1 cm tremor amplitude) in at least two out of three maneuvers of test item 4 (upper limb tremor) confirmed by an independent
  • TETRAS expert by means of video assessment.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 43
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 32

排除标准

  • History or presence of day-to-day fluctuations in ET which would jeopardize meaningful tremor assessment over time, e.g. severe tremor on one day
  • and minimal or no tremor on another day.
  • Other neurological signs, such as dystonia, ataxia, or parkinsonism, which in the judgment of the investigator could interfere with the ET diagnosis
  • and/or assessment of ET in ULs.
  • Tremor types other than ET

研究者

相似试验

招募中
4 期
Prospective, randomized, double-blind, placebo-controlled, multicenter clinical investigation to determine the clinical performance and safety of Luvos® Healing Earth in patients with histamine-mediated recurrent digestive symptoms.T78.1T62K58K59Other adverse food reactions, not elsewhere classifiedToxic effect of other noxious substances eaten as foodOther functional intestinal disordersIrritable bowel syndrome
DRKS00027333Heilerde-Gesellschaft Luvos Just GmbH % Co. KG114
进行中(未招募)
1 期
Cineole in acute non-purulent rhinosinusitis
EUCTR2016-002743-41-DEEngelhard Arzneimittel GmbH & Co. KG250
进行中(未招募)
不适用
Clinical study to investigate the efficacy and safety of NT 201 compared to placebo in the treatment of chronic troublesome drooling associated with neurological disorders and/or intellectual disabilityChronic troublesome sialorrhea associated with neurological disorders (e.g. cerebral palsy, traumatic brain injury) and/or intellectual disability in children and adolescentsMedDRA version: 18.0Level: PTClassification code 10039424Term: Salivary hypersecretionSystem Organ Class: 10017947 - Gastrointestinal disorders
EUCTR2013-004532-30-Outside-EU/EEAMerz Pharmaceuticals GmbH249
进行中(未招募)
1 期
Clinical study to investigate the efficacy and safety of NT 201 compared to placebo in the treatment of chronic troublesome drooling associated with neurological disorders and/or intellectual disability
EUCTR2013-004532-30-HUMerz Pharmaceuticals GmbH249
进行中(未招募)
1 期
Study to compare the efficacy and safety of NT 201 (botulinum toxin) with placebo for the treatment of lower limb spasticity caused by stroke or traumatic brain injury.Diagnosis of lower limb spasticity with or without upper limb spasticity of the same body side caused by stroke or traumatic brain injuryMedDRA version: 20.0Level: LLTClassification code 10058977Term: Spastic paresisSystem Organ Class: 100000004852
EUCTR2018-001639-35-ITMerz Pharmaceuticals GmbH600